Editors of Blood Select Top 10 Manuscripts from 2016
Studies Include Advancements in Chimeric Antigen Receptor T Cells, Gene Therapy, and Genetic Sequencing
This year, there have been more than 1,000 manuscripts published in Blood, the Journal of the American Society of Hematology. To recognize these achievements, Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD, have selected the top 10 most outstanding manuscripts of 2016.
“From harnessing the immune system to target untreatable diseases to honing cutting-edge genome editing techniques to correct genetic defects, the promise of cures for many diseases starts with a better understanding of the blood,” said Dr. Löwenberg. “Recognizing hematology as the home of some of science’s most groundbreaking advances, and Blood’s role as the top-cited journal of our field, we are proud to look back at the top papers of 2016.”
To identify the following top manuscripts of the year, the editors considered quality of the work and interest to the field of hematology, judged by how often the paper was accessed or cited. The following articles are listed in no particular order.
- Postibrutinib outcomes in patients with mantle cell lymphoma; Martin et al.
- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial; Santagostino et al.
- Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms; Araki et al.
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma; Krejcik et al.
- Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease; Hoban, Orkin, and Bauer.
- Toxicities of chimeric antigen receptor T cells: recognition and management; Brudno and Kochenderfer.
- A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders; Simeoni et al.
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma; Ali et al.
- Evolution of acute myelogenous leukemia stem cell properties after treatment and progression; Ho et al.
- A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia; Lichtenstein et al.
Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the flagship journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.
ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.
blood® is a registered trademark of the American Society of Hematology.
CONTACT:
Stephen Fitzmaurice, American Society of Hematology
[email protected]; 202-552-4927
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission